

PEPFAR/Ukraine

COP Review Out-Brief

April 26, 2017



A New Era of Accountability, Transparency, and Solidarity to Accelerate IMPACT

Stakeholder Engagement

Stakeholder collaboration is key to progress in Ukraine

- Constant dialogue with civil society and GOU public health
- Mutual support especially in times of crisis

Overview of stakeholder engagement in COP17

- COP guidelines shared - Jan 3rd (draft) and January 18
- January 25th – National Stakeholder Mtg sponsored by GFATM, UNAIDS and PEPFAR
- DCOMM materials shared on March 10th
 - Limited but useful feedback
 - Ongoing interaction with MoH on commodity need with adjustments in COP submission.
- Team reached out to CSO participants in COP review
- PEPFAR staff participating in some GFATM CN work groups (e.g. SI, Laboratory)
- PEPFAR implementing partners supporting GFATM PRs and CN




Section 1: Brief review of useful context




Political & Economic Context

- Continued war in the east, geopolitical pressures
- Return to low level of economic growth after 50% drop in GDP (USD)
- Health Reform is progressing despite challenges from vested interests
 - Initial focus on primary care with introduction of capitation
 - Steps towards rationalization of health services
 - Recent attacks on the Acting Minister of Health fended off


PWID in Ukraine Cascade, 2016



MSM in Ukraine Cascade, 2016




FSW in Ukraine Cascade, 2016




Increasing reported contribution of heterosexual HIV transmission

- Since 2007, increasing majority of HIV cases reported as heterosexually acquired
- No standard risk factor ascertainment
- Stigma around MSM and IDU behavior remains high





Proportions of recently registered cases among males by mode of transmission by ascertainment method MOT study preliminary results






Age and gender distribution of PLHIV and ART patients, Ukraine

Age

- 15 – 24 years:
 - SPECTRUM estimates: 5.9% of adult PLHIV
 - Case registration data: 5.7% of adult cases in 2015


Gender

- SPECTRUM estimates: 45% of PLHIV are female
- Nat'l ART data Mar 1 2017
 - 35,280 women: 47% of ART patients
 - 39,470 men: 53% of ART patients
- Of 8,303 PEPFAR ART patients (Jan 2017), 50% men and 50% women





Ukraine demographics

- Post independence birth drought
- Smaller cohorts now significant part of child-bearing population
- Absolute numbers of cases among <25 useful but needs careful interpretation
- Incidence rate proxy for population important



IBBS – HIV prevalence



REDACTED



❖ *What have we been doing and what are we learning from it*

Major Shifts COPs 15 and 16


COP 15

1. Treatment cascade
 - a) Increased detection –network recruiting of PWID
 - b) Increased linkage to care – peer CM to AIDS centers
 - c) Relinkage LTFU
2. Focus on 5 priority oblasts, plus 6 medium burden oblasts
3. Focus on PWID and partners
4. Scale up of QI interventions in AIDS Centers
5. Pilots of PITC, partner testing
6. ART commodities

COP 16

1. ART treatment specific TA support
2. Additional ART commodities
3. Kyiv FTCl
4. Continued focus on
 - a) Policy reforms
 - b) Procurement
 - c) Data
 - d) Laboratory
 - e) Health reform


Q1-Q2 Testing and Treatment Continuum



All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.

A New Era of Accountability, Transparency, and Solidarity to Accelerate IMPACT

ART scaleup continues: Ukraine national results




All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.

RESPOND regions
 HTC_POS data reported from ART sites
 includes preliminary FY17Q2 data

HIV Detection: number and proportion tested positive, 2015–2017

Among 20 QI sites where
 OCF/CITI clients got a diagnosis: 164 (8%) from OCF/CITI
 7 regions, 135 QI sites



◆ Number of people tested positive
 — Number tested positive, 2015 median
 ■ Testing yield, %
 — Detection rate, 2015 median


RESPOND regions

Registration and ART Initiation

includes preliminary FY17Q2 data, inclusive of OCF-CITI


ARV availability

Registration at AIDS Service and Initiation on ART, 2015–2017



All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.


From OCF to CITI January 2016- March 2017



All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.

A New Era of Accountability, Transparency, and Solidarity to Accelerate IMPACT

Cascade within CITI, January 2016 – March 2017




All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.


A New Era of Accountability, Transparency, and Solidarity to Accelerate IMPACT

CITI NGO Performance by Regions, Q2 FY17

Dnipropetrovsk Oblast by NGO Performance



Kyiv City by NGO Performance




All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.

A New Era of Accountability, Transparency, and Solidarity to Accelerate IMPACT

SIMS visit: Mykolaiv oblast; Voznesensk

- Useful details not part of SIMS assessment
 - Rapid initiation on therapy after registration
 - Highly successful ‘index’ testing via dedicated, engaged HCW
 - Suggestive evidence of improving epidemic situation
 - Increasing testing; lower yields
 - Good partner recruiting
 - Decreasing number of patients with very low CD4 counts; seeing more absolute number of patients with higher CD4



SIMS visit: Mykolaiv oblast AIDS Center

- Discussed high volume site with low ART rate (Vitovska). She had over past year
 - Removed low performing MD
 - Covered site in interim
 - Recruited promising young MD
- Had identified dropout of rural ART patients ~2/3 at 12 months
 - Identified lack of transport
 - Made agreements with all regions lacking ART site to dispense ART at CRH

Treatment site	Registered PLHIV	PLHIV on ART	PEPFAR ART	% reg'd on ART
Mykolaiv oblast overall	8381	5296	263	63%
Миколаївський обласний центр СНІДу	4396	3053	156	69%
Вознесенська ЦРЛ	569	399	4	70%
ДЗ "СМЧ №2" м.Южноукраїнськ	340	254	7	75%
Первомайська ЦРЛ	197	127	6	64%
КЗ "Первомайський міський центр ПСМД"	471	348	27	74%
Баштанська ЦРЛ	172	119	10	69%
Новобузька ЦРЛ	170	90	6	53%
Миколаївська ЦРЛ	285	125		44%
Новоодеська ЦРЛ	162	58		36%
Очаківська ЦРЛ	165	123	10	75%
Vitovska central rayon hospital	1303	468	18	36%
Миколаївський обласний протитуберкульозний диспансер	151	132	19	87%



National Stakeholder Joint Action

In the last year, strong coordinated efforts have led to:

- ❖ Successfully passing larger government budget for HIV that includes increased support for ARVs
- ❖ GoU agreement to buy limited amount of MAT
- ❖ Country commitment to rejoin UNAIDS Fast Track trajectory by 2018, if PEPFAR and other donors continue to support scale up of treatment

PEPFAR support for improving ART policy

- Evidence Workshop, April 3-7 2017
 - 25 high level AIDS center representatives
 - ARV experts: ITECH, WHO and CDC
 - Opinion shift away from LPV/r
 - To be repeated June, Sep 2017
- Verbal acceptance of outside review of draft clinical protocol



Progress in policy environment

ART guidelines

- Treat all
- Multi-month ARV dispensing
- Task shifting

Self-testing

- Availability of self-test kits
- Monitor adherence to self-testing SOPs and Q/C
- Post-marketing validation/surveillance

Public health approach

- NCPH and NGOs support PH approach
- Resources and attention to KPs
- Attention to PH approach through HC reform

Public health system

- Strengthen National Center for Public Health
- Network of regional PH centers
- 1° and 2° service delivery reform and HIV




Kyiv FTCI at 1 year



- 2017-2021 HIV/TB program approved with 90-90-90 targets
 - Planned expansion of ART from 6,693 (January 2017) to 21,804 (2021)
- Private funding to support 1,700 ART patients
- 54 Million USD budgeted (19% national budget, 16% Kyiv budget, rest – other inc international)
- Kyiv budget will begin support for MAT
- Expansion of MAT with PEPFAR support
- Pilot PrEP for MSM with PEPFAR support

ART patients



- March 2017: Odesa joins FTCI



❖ *What are we planning to do for maximum impact*

A New Era of Accountability, Transparency, and Solidarity to Accelerate IMPACT



PEPFAR Ukraine Vision for COP 17 Strategy

Continued rapid expansion of ART with

- Additional 15,000 patients to be started on PEPFAR ARVs
- Transition of ECF and COP 16 PEPFAR patients to GoU ARVs

Augmented/new program directions to bring in add'l PLHIV for ART

- Increased support of MSM testing and linkage in high burden cities
- Direct support of large scale expansion of PITC and partner testing
- Development and support of program to improve linkage for KPs
- Development and support of program for demand creation

Development of improved adherence activities to minimize LTFU

Initiating treatment activities towards test and start, decentralization and optimization

Continued policy and health system reform to create sustainability



COP16-17 Target Comparison

	COP16 (FY17) Target	COP17 (FY18) Target	COP 17 as % of COP16
People tested	87,035	125,169	144%
People identified	3,638	10,039	276%
Treatment NEW	20,786	40,956	197%
Treatment Current	38,766	100,860	260%
OVC Served	350	400	114%
KP Prevention	34,286	43,899	128%
KP MAT	3,025	3,281	108%
PP Prevention	2,752		
TB cases with known HIV status	5,488	6,961	127%
HIV+ TB on ART		1,863	
Total Budget	\$37,608,888	\$37,742,042 (including performance funding)	


FY17 HTC_TST & HTC_POS target does not include OCF (was custom target but likely to be included in some of facility results); and includes only half year for USAID/RESPOND work at ART sites (project then extended)

Summary of COP17 Targets by Prioritization

COP17 Priority	COP17 Target (APR18) HTC_Test	COP17 Target (APR18) HTC_Pos	COP17 Target (APR18) Tx_New	COP17 Target (APR18) Tx_CURR	COP17 Target (APR18) OVC_Serv	COP17 Target (APR18) KP_Prev	COP17 Target (APR18) KP_MAT	COP17 Target (APR18) TB_STAT	COP17 Target (APR18) TB_ART
TOTAL	125,169	10,039	40,956	100,860	400	43,899	3,281	6,961	1,863
Attained									
Saturation	2,893	261	2,280	7,217	40	1,612	245	878	256
Aggressive	92,276	9,178	38,676	93,643	360	42,287	3,036	6,083	1,607
Sustained									
Other	30,000	600							

A New Era of Accountability, Transparency, and Solidarity to Accelerate IMPACT

COP 2016 vs COP 2017 Budget Code Totals




A New Era of Accountability, Transparency, and Solidarity to Accelerate IMPACT



Achieving the 2nd 90: ART targets in oblasts targeted for saturation

- 2018 targets require
 - Increased recruitment
 - Increased access to ART services
 - ARV commodities




All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.



Achieving the 2nd 90: Sources of patients for Tx_NEW , Dnipropetrovsk Oblast, FY18

- Previously diagnosed patients significant source
- Current rates of new registered patients insufficient
- Additional ~2500 ART patients needed from new and enhanced PEPFAR testing activities






Finding slots: increasing access to ART for PLHIV

- Current ART system based on ID physicians in AIDS centers
 - Average no. of ART patients per MD up to 800
- Models for increasing access to ~80% increase in ART patients by end 2018
 - AIDS centers
 - Potential for adding new ID MDs in AIDS centers modest
 - Differentiated services
 - Task shifting within MDT
 - Decentralization to ID physicians in non HIV specialty settings – example of Krivy Rih
 - Primary care physicians for either follow-up or initiation for uncomplicated patients – under consideration

Change in number of ART patients at nonAIDS center sites, Krivy Rih




All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.




Finding drugs: ARV for expansion of treatment, Ukraine

- PEPFAR ARVs dominant factor in scaleup 2016 - 2018
- Favorable trends in GoU ability to cover ART needs
 - Increase in GOU funding
 - Optimization of regimens leading to decreasing avg. prices
 - Fierce advocacy leading to new drugs, better prices







Expansion to government controlled areas (GCA) of Donetsk Oblast



Distribution of estimated PLHIV, by subnational units, Ukraine 2016
 (USG/CDC in-house estimates)



PEPFAR support for expansion of ART



TX_CURR and TX_NET NEW USAID/RESPOND, 8 oblasts


Oblast	TX_NEW				TX_CURR					TX_NET_NEW	
	FY17Q1	FY17Q2	FY17 target	TX_NEW % achievement	FY16Q4	FY17Q1	FY17Q2	FY17 target	TX_CURR % achievement	Q4-Q1	Q1-Q2
Total	4,143	4,151	18,749	44%	38,850	43,578	45,834	31,626	145%	4,728	2,256
Dnipropetrovsk	1,375	1,594	6,495	46%	11,180	12,097	13,199	11,234	117%	917	1,102
Odesa	598	727	5,408	25%	9,304	10,062	10,255	7,962	129%	758	193
M. Kyiv	896	695	3,480	46%	5,929	6,693	7,007	5,941	118%	764	314
Zaporozhzhya	231	140	956	39%	2,253	2,419	2,535	1,354	187%	166	116
Kherson	147	176	878	37%	2,186	2,250	2,333	1,331	175%	64	83
Mykolayiv	360	309	628	107%	4,855	5,221	5,284	1,078	490%	366	63
Kirovohrad	143	162	536	57%		1,342	1,493	796	188%		151
Kyiv Ob	393	348	368	201%	3,143	3,494	3,728	1,930	193%	351	234

RESPOND started QI work in Kirovohrad in FY17Q1

All PEPFAR FY 2017 Q2 program results and achievements included within this presentation were based upon preliminary reporting and may differ from the final submission results. Final FY 2017 Q2 results, as well as past and future quarterly and annual PEPFAR program results, can be accessed on the PEPFAR Dashboard at <http://data.pepfar.net>.

Achieving the 1st 90: Testing vision and targets

- Analysis indicates
 - Most previously diagnosed patients being brought onto ART by 2018
 - Current testing insufficient in reach and yield to meet treatment targets
 - New approaches needed
- Planned PEPFAR testing
 - Intensified expanded OCF
 - Initiation of large scale PITC
 - Expansion of index testing
 - Expansion and improvement of MSM testing activities
 - Enhanced prison testing and linkage
 - Continued military testing



GF outreach testing yields H1 2016 12 oblasts: 41
PWID 1.9%; MSM 0.7%



PITC and index testing, Ukraine pilot results

PITC testing


- PITC not common in most facilities (except AIDS centers, TB)
- Pilot through RESPECT
 - Selected medical facilities in 3 oblasts
 - 2133 patients tested
 - 528 (25%) seropositive
 - Pilot being extended to better characterize factors for success

Index testing

Fairly uncommon, pilot through RESPOND

- Significant number of partners per index client
- 11% yield among partners tested
- >75% linkage to AIDS centers

HTS & Linkage to Care for Sexual Partners of PLHIV






MSM Testing Considerations


- MSM concentrated in Kyiv City, Odesa, and Dnipro
 - 1/3 of est MSM and >40% of est MSM PLHIV nat'l
- In Kyiv and Odesa evidence of rapid transmission
 - Increase in prevalence 2013 – 2015 IBBSs
 - Incidence by Lag 2013 IBBS
 - Kyiv City 5%, Odesa 4%
 - Supports > 5,000 undiagnosed HIV-positive MSM in these regions

•

Friendly Doctor MSM HTS activity




Strategies for improving linkage for the hardest to reach populations— *based on lessons learned*



Achieving the 3rd 90 in Ukraine: ART Retention

- Longitudinal f/u of annual cohorts
- 12 month LTFU
 - National 86%
 - ~ 50% of LTFU (Yr 1) due to mortality
 - Kirovograd lowest
- Longer term retention is measured cumulatively – plateau in LTFU




Achieving the 3rd 90 in Ukraine: VL suppression 2016

- **2016 data**


- 50,000 patients on ART > 6 mos who had VL
- National – 90%

- **Kirovograd lowest VL suppression**

- **VL test kits no longer limiting factor**



HIV Viral load scale-up in Ukraine



#VL tests per day/per instrument in 2017

Region/lab	#VL tests /day/instrument
Dnipropetrovs'ka	150
Donets'ka	95
Odessa	215
Kyiv City	162
NRL	131

year	#VL tests	#of equipped labs
2008	28 032	10
2009	34 255	10
2010	61 408	12
2011	69 833	16
2012	95 655	18
2013	132 115	18
2014	78 101	18
2015	55176	19 (-3 <i>Crimea, Luhansk and Donets'k labs are currently in non-Ukraine-government-controlled-area</i>)
2016	98561	17 (+1 <i>Cherkassy</i>)
2017	295100 (projected)	18 (+1 <i>Sloviansk</i>) + 8 (3 new from <i>Abbot</i> and 5 from <i>Roche</i> in progress)

Achieving the 3rd 90 in Ukraine

Additional activities COP 17

- **Health Link**

- Retention and adherence work including formative KP research

- **MAT**

- Improving retention on MAT

- **Mental health**


- Piloting standardized approach to diagnosing and initial treatment of depression in 4 sites

- **HIV Drug Resistance survey**

- In collaboration with CDC-Atlanta and WHO

Prevention Activities: MAT

- **GOU assumption of >8,000 MAT patients in 2017**
- **Coverage still low (3% of est PWID)**
 - Further scaleup needs advocacy
 - Increased local support
 - Increased co-pay options
- **PEPFAR activities include**
 - increasing quality of services
 - co-location of services
 - linkage to ART



Prevention: PrEP

- **MSM in Kyiv and Odesa**
 - >3% incidence rate
 - Self-testing to be introduced
 - Centrally funded award to improve cascade including T&S component
- **COP 17 includes**
 - Truvada and testing commodities
 - Targets 500 PEPFAR, 3500 GOU

Activities: OVC Peace Corps

- Regional and national clubs for OVC and caregivers
- OVC-related leadership camp
- Trainings for service providers, SW, teachers, medical students - on HIV and stigma reduction
- Volunteer grants
 - stigma reduction; KP issues, youth prevention
- 2 trainings on fighting stigma and discrimination, support of OVC and KPs, KP HIV-prevention
- Peace Corps Response— capacity development of NGOs working with KPs

OVC reached Q4 FY 16 and Q1 FY17




Table 6

Commodity insecurity (\$2.0M)	<ul style="list-style-type: none">• Increase domestic resources for commodities• Build supply chain management capacity• Optimize ART regimens
Detection, linkage, retention (\$2.3M)	<ul style="list-style-type: none">• Expand OCF to new oblasts, MSM• Pilot and expand PITC, index testing• Roll out case management• Expand MIS for better data and tracking
Health system reform (\$2.4M)	<ul style="list-style-type: none">• Strengthen NPHI• Reform health financing• Decentralize HIV services
Test and start (\$0.9M)	<ul style="list-style-type: none">• Develop guidelines• Costing and budgeting test and start• Determine HR requirements
Service delivery models (\$0.4M)	<ul style="list-style-type: none">• Expand primary care• Pilot innovative MAT models• Pilot PrEP in MSM• Standardize testing and linkage in military

HIV MIS roll-out summary

#	Region	Sites operating	Work stations operating	Staff trained	Sites to be started	Work stations to be installed	Staff to be trained	Timeline
1	Cherkassy oblast	24	57	68				Jan-Apr 2017
2	Chernihiv oblast	15	42	38	14	14	40	Feb-May 2017
3	Kyiv City	5	60	92	5	5	8	2016, Jan-Apr 2017
4	Dnipropetrovsk oblast				29	116	130	July-Oct 2017
5	Kherson oblast				12	33	57	Apr-Jul 2017
6	Kirovograd oblast				22	42	60	Sept-Dec 2017
7	Kyiv oblast			24	17	60	40	Mar-Jun 2017
8	Mykolaiv oblast				34	75	103	Apr-Jul 2017
9	National level clinic				1	19	25	Dec 2017- Mar 2018
10	Odessa oblast	30	84	60			30	Jan-Apr 2017
11	Vinnitsa oblast	5	35	52	1	1	2	2016, Mar, 2017
12	Zaporizhzhya oblast				17	83	90	Aug -Nov 2017
13	Poltava oblast	36	68	107		10	10	2016
	TOTAL	115	346	441	152	458	595	

Commodities

Product	COP16 Investment	COP17 Investment
HIV test (RTKs including self-testing) Urine tests for drugs of abuse	N/A	\$.27 M USD
ARV DRUGS	\$8 M (budgeted)	\$2.6 M USD (PrEP = \$335,040)
CD4/VL Reagents/consumables	\$2.4 M (budgeted)	\$2.4 M USD
TOTAL	\$10.4 M USD	\$5.27 M USD

Difference b/w 2016 and 2017 is approximately \$5.1 M USD

Performance funds

OBJECTIVE: Scale up for additional 15,000 PLHIV and expansion of program activities to Donetsk

COMMODITIES:

- 2.7 M USD for 1ST AND 2ND LINE ARV DRUGS (HXTD)
- 1 Million for VL reagents (HTXD)

ACTIVITIES:

- EXPANSION OF OCF TO ADDITIONAL KP POPULATIONS TO DONETSK
- SCALE UP OF PITC

Budget Code	TBB	Commodities	Above	Site	PM,SI	M&O	Total	Applied Pipeline	New
Male Circumcision	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Adult Care and Support	\$0	\$0	\$160 000	\$280 000	\$320 000	\$0	\$760 000	\$0	\$760 000
Orphans and Vulnerable Children	\$0	\$0	\$0	\$114 000	\$10 000	\$0	\$124 000	\$11 254	\$112 746
Lab	\$0	\$0	\$1 100 000	\$1 845 060	\$270 000	\$0	\$3 215 060	\$330 000	\$2 885 060
Adult Treatment	\$0	\$2 439 401	\$1 290 000	\$2 080 000	\$735 000	\$0	\$6 544 401	\$205 000	\$6 339 401
ARV Drugs	\$0	\$2 605 290	\$0	\$0	\$0	\$0	\$2 605 290	\$0	\$2 605 290
Counseling and Testing	\$630 407	\$365 330	\$639 216	\$1 851 802	\$620 000	\$0	\$4 106 755	\$3 425	\$4 103 330
Management & Operations	\$0	\$0	\$0	\$0	\$0	\$5 693 383	\$5 693 383	\$1 377 203	\$4 316 180
Other Sexual Prevention	\$35 000	\$0	\$100 000	\$320 000	\$110 000	\$0	\$565 000	\$80 000	\$485 000
Strategic Information	\$0	\$0	\$2 572 476	\$599 099	\$1 900 000	\$0	\$5 071 575	\$511 575	\$4 560 000
TB/HIV Care	\$0	\$0	\$168 000	\$360 000	\$140 000	\$0	\$668 000	\$0	\$668 000
Injecting and Non-Injecting Drug Use	\$224 814	\$4 950	\$595 236	\$500 000	\$460 000	\$0	\$1 785 000	\$100 000	\$1 685 000
Mother to Child Transmission	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Health Systems Strengthening	\$90 970	\$0	\$3 505 000	\$200 000	\$2 077 608	\$0	\$5 873 578	\$20 000	\$5 853 578
Pediatric Care and Support	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Pediatric Treatment	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Blood Safety	\$0	\$230 000	\$300 000	\$150 000	\$50 000	\$0	\$730 000	\$230 000	\$500 000
Injection Safety	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Abstinence/Be Faithful	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
	\$981 191	\$5 644 971	\$10 429 928	\$8 299 961	\$6 692 608	\$5 693 383	\$37 742 042	\$2 868 457	\$34 873 585
	3%	15%	28%	22%	18%	15%	100%		

Earmark Allocations

- **New FY 2017 funds allocated to care and treatment: \$11,603,690**
 - COP 2017 requirement: \$9,509,314 (exceeded)
- **New FY 2017 funds allocated to OVC: \$112,746**
 - COP 2017 requirement: \$112,746 (met)
- **New FY 2017 funds allocated to water: N/A**
 - COP 2017 requirement: **N/A**
- **New FY 2017 funds allocated to GBV: N/A**
 - COP 2017 requirement: **N/A**

Дякую!

